Chronic Proton Pump Inhibitor Use Leading to Refractory Hypomagnesaemia in a Patient with Rheumatoid Arthritis: A Case Report

Main Article Content

Rizwanullah
Muzamil Khan
Radhika Bassi
Samah Badr Hamad
Reem Eisa
Henna Patel

Keywords

Proton pump inhibitors, PPI-induced hypomagnesaemia, magnesium depletion, prolonged PPI usage, Hayatabad Medical Complex, refractory hypomagnesaemia, intravenous magnesium supplementation

Abstract

The widespread utilization of proton pump inhibitors has surged in recent times, making them one of the most frequently prescribed medications. Magnesium, a crucial intracellular cation, contributes to numerous cellular functions. Depleted magnesium levels can trigger a range of adverse events. The cause of hypomagnesaemia associated with proton pump inhibitors remains uncertain. A 43-year-old female presented Out Patient Department (OPD) of Hayatabad Medical Complex, with a range of symptoms including weakness, anorexia, lethargy, tremor, and muscle fasciculation. She is a diagnosed case of Rheumatoid Arthritis. Following her Rheumatoid Arthritis diagnosis, she commenced prednisone treatment, which induced epigastric pain. Consequently, she initiated proton pump inhibitors usage for a prolonged period of 12 years, leading to PPI-induced hypomagnesaemia. The objective of this study is to avoid unnecessary use of PPIs and if someone use it for chronic condition then Magnesium level should be assessed during that time to avoid any dreadful complication of hypomagnesaemia like arrhythmias.

Abstract 248 | PDF Downloads 98

References

1. Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther. 1999; 13 Suppl 3:3-10.
2. Playford RJ, Podas T, Modlin I. Pantoprazole, Prout and the proton pump. Hosp Med. 1999; 60:500-504.
3. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash). 2000;40:52-62.
4. Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101:445-448.
5. Danziger J, William JH, Scott DJ, et al. Proton pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int. 2013;83(4):692-699.
6. Luk CP, Parsons R, Lee YP, et al. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother. 2013;47(6):773-780.
7. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19:25-35.
8. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528-534.
9. Hess MW, de Baaij JH, Broekman MM, et al. Common single nucleotide polymorphisms in transient receptor potential melastatin type 6 increase the risk for proton pump inhibitor-induced hypomagnesemia: a case-control study. Pharmacogenet Genomics. 2017;27:83-88.
10. Gommers LM, Hoenderop JG, de Baaij JH. Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol (Oxf). 2022;235
11. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355:1834-1836.
12. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors--a review. Neth J Med. 2009;67:169-172.
13. FDA Drug Safety Communication. Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). Available from: http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm.

Most read articles by the same author(s)